Acorda

Acorda's stock scraped a 52-week low after analysts at Piper Jaffray cut Acorda's stock-investment rating to "underweight" from "neutral," citing reduced sales expectations for its Ampyra multiple sclerosis drug.

Options Traders Bet on Cooling Tyco Chris Dieterich 2011

Acorda reported holding $228 million in cash, cash equivalents and short-term investments as of June 30, up from $216 million a year earlier.

In Carnage, Cash Comforts Vipal Monga 2011

Ron Cohen , 55 years old, CEO of Hawthorne, N.Y.-based Acorda Therapeutics Inc., says he still remembers his first firing, when he was just 31 years old.

Bad Call: How Not to Fire an Employee Dana Mattioli 2011

Meanwhile, contrarian sentiment surrounded Acorda Therapeutics Inc. options a day after the Hawthorne, N.Y., biotechnology company reported fourth-quarter results.

Options Traders Bet on Cooling Tyco Chris Dieterich 2011

At biotechnology company Acorda Therapeutics Inc., Chief Executive Ron Cohen said spending cash now is risky, because interest rates could rise as a result of the downgrade, making capital more expensive.

In Carnage, Cash Comforts Vipal Monga 2011

Overall volume in Acorda options was more than five times the daily average.

Options Traders Bet on Cooling Tyco Chris Dieterich 2011

Earlier this year, Acorda started selling a drug designed to improve walking in patients with MS. The next frontier of treatment, Dr. Cohen said, will be repairing damage that has already been done to the nervous system.

Novartis's MS Drug Wins U.S. Approval 2010

Acorda and others are developing drugs that attempt to do this by helping the body make new myelin.

Novartis's MS Drug Wins U.S. Approval 2010

However, that drug from Acorda Therapeutics is designed to improve walking ability, rather than treat the underlying disease.

FDA Approves Drug For Multiple Sclerosis 2010

"Acorda, Simpatico" is a romantically fateful track worth downloading.

Phil Ramone and Danielle Evin: Dog Ears Music: Volume Seventy-Nine 2009